Ngenla (Somatrogon)

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Prescription Required

  • Product Details


    Your doctor may prescribe Ngenla, a human growth hormone (HGH) analog, for treating growth failure in pediatric patients three and older. Ngenla is used in patients with low secretion of endogenous growth hormone.

    Ngenla works by mimicking the natural HGH hormone, binding to the growth hormone (GH) receptor, and initiating a signal cascade that stimulates increased growth and metabolism.


    Ngenla's dosage is adjustable based on individual dosing requirements. The recommended frequency is once weekly, with an initial dosage of 0.66 mg/kg.

    Ongoing dosage adjustments are made in response to observed growth.

    To prevent abnormal fat tissue growth, injection sites should be rotated regularly.

    Administered through prefilled pens containing 24 mg or 60 mg.


    The active ingredient in Ngenla is somatrogron.


    Common drug-drug interactions with Ngenla may include:

    • Acarbose
    • Albiglutide
    • Alclometasone
    • Alogliptin
    • Amcinonide
    • Beclomethasone
    • Betamethasone
    • Budesonide
    • Canagliflozin
    • Chlorotrianisene
    • Chlorpropamide
    • Ciclesonide
    • Clobetasol
    • Clobetasone
    • Clocortolone
    • Cortisone
    • Dapagliflozin
    • Deflazacort
    • Desonide
    • Desoximetasone
    • Dexamethasone
    • Diethylstilbestrol
    • Diflorasone
    • Diflucortolone
    • Difluprednate
    • Dulaglutide
    • Empagliflozin
    • Ertugliflozin
    • Esterified Estrogens
    • Estradiol
    • Estramustine
    • Estropipate
    • Ethinyl Estradiol
    • Exenatide
    • Flucloronide
    • Flumethasone
    • Flunisolide
    • Fluocinolone
    • Fluocinonide
    • Fluocortin
    • Fluocortolone
    • Fluorometholone
    • Flurandrenolide
    • Fluticasone
    • Glimepiride
    • Glipizide
    • Glyburide
    • Halcinonide
    • Halobetasol
    • Hydrocortisone
    • Insulin
    • Insulin Aspart, Recombinant
    • Insulin Bovine
    • Insulin Degludec
    • Insulin Detemir
    • Insulin Glulisine
    • Insulin Lispro, Recombinant
    • Linagliptin
    • Liraglutide
    • Lixisenatide
    • Loteprednol
    • Medrysone
    • Mestranol
    • Metformin
    • Methylprednisolone
    • Miglitol
    • Mometasone
    • Nateglinide
    • Paramethasone
    • Pioglitazone
    • Pramlintide
    • Prednicarbate
    • Prednisolone
    • Prednisone
    • Quinestrol
    • Repaglinide
    • Rimexolone
    • Rosiglitazone
    • Saxagliptin
    • Semaglutide
    • Sitagliptin
    • Tibolone
    • Tolazamide
    • Tolbutamide
    • Triamcinolone
    • Voglibose


    Caution is advised for individuals with a history of cancer, diabetes, pancreatitis, thyroid disease, or other adrenal problems.

    Regular assessment of intracranial hypertension during treatment is essential.

    Ngenla may lead to fluid retention, requiring frequent monitoring.

    Side Effects

    Common adverse reactions may include:

    • Anemia
    • Angioedema
    • Body fluid retention
    • Cancer
    • Cough
    • Diabetes mellitus
    • Fever
    • Headache
    • Hypoadrenalism
    • Hypersensitivity reaction
    • Hypothyroidism
    • Impaired glucose tolerance
    • Injection site disorder
    • Intracranial tumor
    • Nasopharyngitis
    • Pancreatitis
    • Progression
    • Pseudotumor cerebri
    • Scoliosis deformity of spine
    • Slipped upper femoral epiphysis
    • Vomiting


    Ngenla [package insert]. New York, NY: Pfizer; June 2023.

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14429

  • Product Reviews


Please wait while the page is loading. Do not hit refresh or the browser back button to avoid any loss of information.

If you have any questions or concerns, please contact our Customer Service team via the chat option on our website or calling us toll free at: 1-800-891-0844